akhatri

In response to a significant ongoing disruption to the supply of Adipine® XL 30mg MR tablets and Adipine® XL 60mg MR tablets, two Serious Shortage Protocol (SSP) have been issued by the Department of Health and Social Care (DHSC). SSP084 Adipine® XL 30mg MR tablets Effective today, 19 December 2025, SSP084 provides that for every one Adipine® [...]

The post Two SSPs issued for Adipine® XL 30mg MR tablets and Adipine® XL 60mg MR tablets appeared first on Community Pharmacy England.

In response to a significant ongoing disruption to the supply of Latanoprost 50micrograms/ml / Timolol 5mg/ml (Fixapost®) eye drops 0.2ml unit dose preservative free, a Serious Shortage Protocol (SSP) has been issued by the Department of Health and Social Care (DHSC). Effective today 19 December 2025, SSP086 provides that for every 2.5ml bottle of Latanoprost 50micrograms/ml [...]

The post New SSP issued for Latanoprost 50micrograms/ml / Timolol 5mg/ml (Fixapost®) eye drops 0.2ml unit dose preservative free appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the transition to the new formulation and risk of medication error with Rybelsus® tablets. There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus® tablets, which have different stated mg [...]

The post MHRA Drug Safety Update: Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following products: Rivastigmine 4.6mg/24hours transdermal patches Rivastigmine 9.5mg/24hours transdermal patches MSN/2025/062 Tier 3 – high impact Date of issue: 03/12/2025 Summary Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches are in limited supply until w/c 15 December 2025. Rivastigmine 13.3mg/24hours transdermal [...]

The post Medicine Supply Notification: Rivastigmine 4.6mg/24hours and 9.5mg/24hours transdermal patches appeared first on Community Pharmacy England.